[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-52409-en":3,"doc-seo-52409-105":30,"detail-sidebar-cat-0-en-105":91},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":21,"is_downloadable":21,"audit_status":21,"page_count":22,"language":23,"language_code":24,"site_id":25,"html_lang":24,"table_of_contents":26,"faqs":27,"seo_title":13,"seo_description":14,"update_tm":28,"read_time":29},52409,1099514067438,"River Wang","https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542",7,"Healthcare","RNA Therapeutics The Evolving Landscape of RNA Therapeutics","Edited volume on RNA therapeutics that maps available tools and strategies for modulating cellular processes, including chromatin targeting via saRNA and the molecular basis of RNA interference involving Argonaute and TNRC6. Covers discovery, mechanism of action, and preclinical proof-of-concept studies across metabolic, cardiovascular, genetic, and oncology contexts, progressing to clinical-stage therapeutic saRNA. Discusses targeted RNA delivery approaches for cancer and immunomodulation and extrahepatic delivery of RNA to immune cells using bio-conjugates and nanocarriers, emphasizing therapeutic intervention and immune-cell manipulation.","RNA Therapeutics:The Evolving Landscape ofRNA Therapeutics  \nEdited by  \nPaloma H.Giangrande,Vittorio de Franciscis,John J.Rossi  \nRNA Therapeutics  \nRNA TherapeuticsThe Evolving Landscape ofRNA Therapeutics  \nEdited by  \nPaloma H.Giangrande  \nAdjunct Associate Professor of Internal Medicine,University oflowa,lowa City,IA,United States  \nVice President of Platform Discovery Sciences,Biology,WaveLife Sciences,Cambridge,MA,United States  \nDr.Vittorio de Franciscis  \nSenior Collaborator,National Research Council(CNR),Institute of Genetic and Biomedical Research (IRGB)—UOSMilan Via Rita Levi Montalcini,Pieve Emanuele(M1),Italy  \nJohn J.Rossi  \nProfessor and Chairman,Department of Molecular and CellularBiology,Beckman Research Institute of the City of HopeMonrovia Biomedical Research Center,Monrovia,CA,USA  \nAcademic Press is an imprint of Elsevier  \n125 London Wall,London EC2Y 5AS,United Kingdom525 B Street,Suite 16so,San Diego,CA 92101,United States50 Hampshire Street,sth Floor,Cambridge,MA 02139,United StatesThe Boulevard,Langford Lane,Kidlington,Oxford OX51G8,United Kingdom  \nCopyright ◎2022 Elsevier inc.All rights reserved.  \nNo part of this publication may be reproduced or transmitted in any form or by any means,electronicor mechanical,including photocopying,recording,or any information storage and retrieval system,without permission in writing from the publisher.Details on how to seek permission,furtherinformation about the Publisher's permissions policies and our arrangements with organizations suchas the Copyright Clearance Center and the Copyright Licensing Agency,can be found at our website:www,elsevier.com/permissions.  \nThis book and the individual contributions contained in it are protected under copyright by thePublisher(other than as may be noted herein).  \nNotices  \nKnowledge and best practice in this ficld are constantly changing.As new research and experiencebroaden our understanding,changes in research methods,professional practices,or medical treatmentmay become necessary.  \nPractitioners and researchers must always rely on their own experience and knowledge in evaluatingand using any information,methods,compounds,or experiments described herein.In using suchinformation or methods they should be mindful of their own safety and the safety of others,includingparties for whom they have a professional responsibility.  \nTo the fullest extent of the law,neither the Publisher nor the authors,contributors,oreditors,assumeany liability for any injury and/or damage to persons or property as a matter of products liability,negligence or otherwise,or from any use or operation ofany methods,products,instructions,or ideascontained in the material herein.  \nISBN:g78-0-12-821595-1  \nFor information on all Academic Press publicationsvisit our website at https://www.elsevier.com/books-and-journals  \nPublisher:Andre G.Wolf  \nAcquisitions Editor:Peter B.Linsley  \nEditorial Project Manager:Susan lkeda  \nProduction Project Manager:Kiruthika Govindaraju  \nCover Designer:Victoria Pearson  \nContributors…………………………………………………………………………………………………………………………………………………………xiii  \nSECTION 1 The world of RNA therapeutics: Available  \nRNA tools to modulate cellular processes  \nTargeting chromatin: Transcriptional gene  \nCHAPTER 1  \nactivation(saRNA)……………………………………………………………………………3  \nJon Voutila and Nagy A. Habib  \nDiscovery and mechanism of action………………………………………………………3  \nPreclinical therapeutic saRNA proof-of-concept studies……………5  \nMetabolic and cardiovascular disease…………………………………………………………5  \nGenetic disease…………………………………………………………………………………………………………6  \nOncology……………………………………………………………………………………………………7  \nClinical-stage therapeutic saRNA………………………………………………………………8  \nConclusions……………………………………………………………………………………………10  \nReferences……………………………………………………………………………………………………………………10  \nArgonaute and TNRC6, partners in RNAi……………………17  \nCHAPTER 2  \nSamantha T. Johnson, Krystal C. Johnson,  \nand David R. Corey  \nIntroduction………………………………………………………………………………………………………………………17  \nArg","cbCaig76VxkHfVcv","https://ap.wps.com/l/cbCaig76VxkHfVcv","pdf",37758041,4,1,474,"English","en",105,"# The world of RNA therapeutics: Available RNA tools to modulate cellular processes\n## Targeting chromatin: Transcriptional gene activation (saRNA)\n## Argonaute and TNRC6, partners in RNAi\n## Targeted RNA therapeutics for treatment of cancer and immunomodulation\n## Extrahepatic delivery of RNA to immune cells","[{\"question\":\"What does the book focus on regarding chromatin targeting and saRNA?\",\"answer\":\"The content outlines discovery and mechanism of action for transcriptional gene activation (saRNA), including preclinical proof-of-concept studies and therapeutic areas such as metabolic/cardiovascular disease, genetic disease, and oncology, followed by clinical-stage therapeutic saRNA and overall conclusions.\"},{\"question\":\"How are Argonaute and TNRC6 related to RNA interference in the book?\",\"answer\":\"A dedicated section explains Argonaute and RNAi and describes TNRC6 and RNAi, including tools for analyzing AGO and TNRC6 function with nuclear and cytoplasmic purifications, then a concluding synthesis with references.\"},{\"question\":\"What delivery strategies for targeted RNA therapeutics are covered?\",\"answer\":\"The material describes approaches including lipophilic oligonucleotide conjugates, conjugation with receptor ligands, antibody–oligonucleotide conjugates, DNA/RNA aptamers for targeted delivery, endosomal TLR9-targeted oligonucleotide immunotherapeutics, and concluding perspectives.\"}]",1783643273,1194,{"code":4,"msg":31,"data":32},"ok",{"site_id":25,"language":24,"slug":33,"title":13,"keywords":34,"description":14,"schema_data":35,"social_meta":86,"head_meta":88,"extra_data":90,"updated_unix":28},"rna-therapeutics-the-evolving-landscape-of-rna-therapeutics","",{"@graph":36,"@context":85},[37,53,68],{"@type":38,"itemListElement":39},"BreadcrumbList",[40,44,48,51],{"item":41,"name":42,"@type":43,"position":21},"https://docshare.wps.com","Home","ListItem",{"item":45,"name":46,"@type":43,"position":47},"https://docshare.wps.com/document/","Document",2,{"item":49,"name":12,"@type":43,"position":50},"https://docshare.wps.com/document/healthcare/",3,{"item":52,"name":13,"@type":43,"position":20},"https://docshare.wps.com/document/rna-therapeutics-the-evolving-landscape-of-rna-therapeutics/52409/",{"url":52,"name":13,"@type":54,"author":55,"headline":13,"publisher":57,"fileFormat":60,"inLanguage":24,"description":14,"dateModified":61,"datePublished":62,"encodingFormat":60,"isAccessibleForFree":63,"interactionStatistic":64},"DigitalDocument",{"name":9,"@type":56},"Person",{"url":41,"name":58,"@type":59},"DocShare","Organization","application/pdf","2026-07-15","2026-07-10",true,{"@type":65,"interactionType":66,"userInteractionCount":20},"InteractionCounter",{"@type":67},"ViewAction",{"@type":69,"mainEntity":70},"FAQPage",[71,77,81],{"name":72,"@type":73,"acceptedAnswer":74},"What does the book focus on regarding chromatin targeting and saRNA?","Question",{"text":75,"@type":76},"The content outlines discovery and mechanism of action for transcriptional gene activation (saRNA), including preclinical proof-of-concept studies and therapeutic areas such as metabolic/cardiovascular disease, genetic disease, and oncology, followed by clinical-stage therapeutic saRNA and overall conclusions.","Answer",{"name":78,"@type":73,"acceptedAnswer":79},"How are Argonaute and TNRC6 related to RNA interference in the book?",{"text":80,"@type":76},"A dedicated section explains Argonaute and RNAi and describes TNRC6 and RNAi, including tools for analyzing AGO and TNRC6 function with nuclear and cytoplasmic purifications, then a concluding synthesis with references.",{"name":82,"@type":73,"acceptedAnswer":83},"What delivery strategies for targeted RNA therapeutics are covered?",{"text":84,"@type":76},"The material describes approaches including lipophilic oligonucleotide conjugates, conjugation with receptor ligands, antibody–oligonucleotide conjugates, DNA/RNA aptamers for targeted delivery, endosomal TLR9-targeted oligonucleotide immunotherapeutics, and concluding perspectives.","https://schema.org",{"og:url":52,"og:type":87,"og:title":13,"og:site_name":58,"og:description":14},"article",{"robots":89,"canonical":52},"index,follow",{"doc_id":7,"site_id":25},{"code":4,"msg":5,"data":92},[93,97,101,105,110,115,118,123,128,131,135],{"id":21,"doc_module":4,"doc_module_name":46,"category_name":94,"show_sort_weight":95,"slug":96},"Story & Novel",90,"story-novel",{"id":47,"doc_module":4,"doc_module_name":46,"category_name":98,"show_sort_weight":99,"slug":100},"Literature",80,"literature",{"id":20,"doc_module":4,"doc_module_name":46,"category_name":102,"show_sort_weight":103,"slug":104},"Exam",70,"exam",{"id":106,"doc_module":4,"doc_module_name":46,"category_name":107,"show_sort_weight":108,"slug":109},5,"Comic",60,"comic",{"id":111,"doc_module":4,"doc_module_name":46,"category_name":112,"show_sort_weight":113,"slug":114},6,"Technology",50,"technology",{"id":11,"doc_module":4,"doc_module_name":46,"category_name":12,"show_sort_weight":116,"slug":117},40,"healthcare",{"id":119,"doc_module":4,"doc_module_name":46,"category_name":120,"show_sort_weight":121,"slug":122},8,"Research & Report",30,"research-report",{"id":124,"doc_module":4,"doc_module_name":46,"category_name":125,"show_sort_weight":126,"slug":127},9,"Religion & Spirituality",20,"religion-spirituality",{"id":126,"doc_module":4,"doc_module_name":46,"category_name":129,"show_sort_weight":126,"slug":130},"World Cup","world-cup",{"id":132,"doc_module":4,"doc_module_name":46,"category_name":133,"show_sort_weight":132,"slug":134},10,"Lifestyle","lifestyle",{"id":136,"doc_module":4,"doc_module_name":46,"category_name":137,"show_sort_weight":106,"slug":138},19,"General","general"]